BioinvestGPT ApS · Research use only
Decisive clinical advantage · ADC design
The Clinical GPS of BeatSoC ADC Drug Design and Biomarker Discovery
This page sets out BVCT for ADC design and biomarker discovery: it simulates how each ADC design and patient stratification parameter changes the PFS/OS hazard ratio against standard of care, instead of stratifying responders on retrospective real-world data. It discusses no individual dashboard call. BVCT's track record, frozen on : 674 of 705 scored readouts correct.
Relying on Real-World Data (RWD) to stratify ADC responders is a self-defeating gamble — an attempt to reconstruct a living patient from a flickering silhouette. Because it is built on retrospective noise, RWD remains unknowably biased and has no clinical foresight into the causal biological drivers that actually determine Overall Survival (OS) Hazard Ratio compared with SoC.
In contrast, BeatSoC Virtual Clinical Trials (BVCTs) simulate the causal impact of each ADC design parameter and each patient stratification parameter on clinical effect size HR compared with SoC at 0.1 precision — without any of the inherent biases of RWD. Visit bvct.bioinvestgpt.com to learn more.
RWD has no clinical foresight; BVCT gives you clinical foresight.
The ADC Clinical Battlefield
| Multimodal AI (statistical RWD) | Foresight AI (causal BVCT) | |
|---|---|---|
| ADC design to effect size | NO CLINICAL FORESIGHT. Handles ADC as a static label. Blind to antibody design, linker design, payload design, etc. | 32+ DESIGN AXES. Simulates target-specific, payload-specific, and site-specific clinical impacts to predict precise PFS/OS HR vs. SoC. |
| Stratification to effect size | NO CLINICAL FORESIGHT. Statistical “matching” based on rearview RWD. Cannot predict OS impact for novel cohorts or designs. | CAUSAL CERTAINTY. Simulates indication-specific, line-of-therapy-specific clinical impacts to predict exact PFS/OS HR for specific patient subgroups. |
| Biomarker to effect size | NO CLINICAL FORESIGHT. Retrospective data mining for correlations. Requires historical “training data” to find statistical ghosts. | EX-ANTE VALIDATED. Identifies mechanistic root causes and simulates biomarker-specific clinical impacts on OS/PFS HR before trial readout. |
Stop Guessing. Start Seeing.
Data-driven AI models cannot simulate a Hazard Ratio (HR) vs. SoC without prior clinical data. They are trapped in the silhouette of the past.
Patient-data-free BVCT reliably simulates the impact of every design and biomarker parameter on HR vs. SoC using human-equivalent virtual patients.
Our 705 prospectively timestamped clinical trial outcome predictions have been timestamp-audited with 95.6% ex-ante accuracy, 89.7% ex-ante PPV and 99.1% ex-ante NPV. Visit data.bioinvestgpt.com to learn more.
RWD is unknowably biased and its unreliability is unimprovable; BVCT is verifiably unbiased and its reliability is mathematically optimal.
Zero Hallucination. Gold-Standard Reliability.
The chance of BVCT’s ex-ante prediction track record being a “lucky guess” is below 2−181 — more than 9.0 × 1015 (253) times lower than the chance of a “lucky guess” breaking 128-bit encryption (AES-128), a widely used encryption standard (2−128), and lower even than the chance of picking one specific atom out of the entire planet Earth.
Visit bvct.bioinvestgpt.com to discover BeatSoC ADC drug design and stratification biomarkers now.